Schisantherin A attenuates sepsis-induced acute kidney injury by suppressing inflammation via regulating the NRF2 pathway

Life Sci. 2020 Oct 1:258:118161. doi: 10.1016/j.lfs.2020.118161. Epub 2020 Jul 27.

Abstract

Aims: Tubulointerstitial inflammation is recognized as a key determinant of progressive sepsis-induced acute kidney injury (AKI). Schisantherin A (SchA) has been shown to be capable of regulating inflammatory processes. In the present study, we explored the possibility of SchA in preventing lipopolysaccharide (LPS)-induced kidney inflammation and injury.

Materials and methods: AKI was induced by a single intraperitoneal injection of LPS in CD1 mice, administration of SchA was used for treatment. The protective effect of SchA on renal function and inflammation were analyzed respectively; the NRK-52E cell line was employed for the in vitro study and relative molecular mechanism was explored.

Key findings: Administration with SchA markedly attenuated LPS-induced damage on renal function and histopathological changes of the kidney. Additionally, pretreatment with SchA could inhibit the expression of inflammatory factors in the kidneys. In NRK-52E cells, SchA treatment significantly inhibited LPS-induced NF-κB activation and pro-inflammatory cytokine expression. Moreover, SchA could promote NRF2 pathway activation, and further blockade of NRF2 activation reversed the SchA-induced inhibition of NF-κB activation.

Significance: These presented results indicated that SchA may have great potential for protecting against sepsis-induced AKI.

Keywords: Acute kidney injury; Inflammation; Lipopolysaccharide; NRF2; Schisantherin A.

MeSH terms

  • Acute Kidney Injury / drug therapy*
  • Acute Kidney Injury / etiology*
  • Acute Kidney Injury / metabolism
  • Acute Kidney Injury / pathology
  • Animals
  • Anti-Inflammatory Agents / therapeutic use*
  • Cell Line
  • Cyclooctanes / therapeutic use*
  • Dioxoles / therapeutic use*
  • Inflammation / drug therapy
  • Inflammation / metabolism
  • Inflammation / pathology
  • Kidney / drug effects
  • Kidney / metabolism
  • Kidney / pathology
  • Lignans / therapeutic use*
  • Male
  • Mice
  • NF-E2-Related Factor 2 / metabolism*
  • Rats
  • Sepsis / complications*
  • Sepsis / drug therapy
  • Sepsis / metabolism
  • Sepsis / pathology
  • Signal Transduction / drug effects

Substances

  • Anti-Inflammatory Agents
  • Cyclooctanes
  • Dioxoles
  • Lignans
  • NF-E2-Related Factor 2
  • Nfe2l2 protein, mouse
  • schizandrer A